Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 14, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Receives Letter Detailing Intended Purchases of Approximately $24 Million of alfataliglicerase to Treat Gaucher Patients in Brazil

CARMIEL, Israel, Dec. 14, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today that the Company received a letter from Fundação Oswaldo...
December 01, 2016 17:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Investor Call

CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Company will hold an investor conference call on December 2, 2016...
December 01, 2016 16:44 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Private Note Exchanges and Private Placement of Secured Convertible Notes due 2021

CARMIEL, Israel, Dec. 01, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) (the “Company”) announced today the entry into a definitive exchange agreement relating to...
November 30, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Enrolls First Patient in Phase II Clinical Trial of OPRX-106 for the Treatment of Ulcerative Colitis

CARMIEL, Israel, Nov. 30, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been enrolled in its phase II clinical trial...
November 22, 2016 09:24 ET | Source: Protalix BioTherapeutics, Inc.

Alfataliglicerase Approved for Pediatric Indications in Brazil for the Treatment of Gaucher Disease in Children Four years and Older

CARMIEL, Israel, Nov. 22, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX) announced today that the Brazilian National Health Surveillance Agency (ANVISA,...
November 09, 2016 08:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Provides Update and Reports 2016 Third Quarter Results

Patient Enrollment Ongoing for Phase III Fabry Clinical Trial with approximately 10 Patients Currently in Evaluation and Screening Stages Enrollment for the Phase II Cystic Fibrosis Clinical Trial...
October 25, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Doses First Patient in Global Phase III Clinical Trial of PRX-102 for the Treatment of Fabry Disease

CARMIEL, Israel, Oct. 25, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today that the first patient has been dosed in its global phase III clinical...
September 07, 2016 07:00 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Presentation of Results from the Phase I/II Clinical Trial of PRX-102 for the Treatment of Fabry Disease at the Society for the Study of Inborn Errors of Metabolism

CARMIEL, Israel, Sept. 07, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today an oral presentation highlighting the results of the phase I/II...
August 10, 2016 07:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Announces Additional Positive Data from its Phase I/II Clinical Trial for PRX-102 for the Treatment of Fabry Disease

CARMIEL, Israel, Aug. 10, 2016 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE MKT:PLX) (TASE:PLX), announced today additional positive data from its phase I/II clinical trial of...
August 08, 2016 16:30 ET | Source: Protalix BioTherapeutics, Inc.

Protalix BioTherapeutics Reports Second Quarter 2016 Financial Results

Patient Screening Underway for Fabry Phase III Clinical Trial Data from the Cystic Fibrosis Phase II Clinical Trial Expected Around Year-End CARMIEL, Israel, Aug. 08, 2016 (GLOBE NEWSWIRE) --...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right